Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25,122 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Institutional clinical trial accrual volume and survival of patients with head and neck cancer.
Wuthrick EJ, Zhang Q, Machtay M, Rosenthal DI, Nguyen-Tan PF, Fortin A, Silverman CL, Raben A, Kim HE, Horwitz EM, Read NE, Harris J, Wu Q, Le QT, Gillison ML. Wuthrick EJ, et al. Among authors: wu q. J Clin Oncol. 2015 Jan 10;33(2):156-64. doi: 10.1200/JCO.2014.56.5218. Epub 2014 Dec 8. J Clin Oncol. 2015. PMID: 25488965 Free PMC article. Clinical Trial.
A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer.
Rodriguez CP, Wu QV, Voutsinas J, Fromm JR, Jiang X, Pillarisetty VG, Lee SM, Santana-Davila R, Goulart B, Baik CS, Chow LQM, Eaton K, Martins R. Rodriguez CP, et al. Among authors: wu qv. Clin Cancer Res. 2020 Feb 15;26(4):837-845. doi: 10.1158/1078-0432.CCR-19-2214. Epub 2019 Dec 3. Clin Cancer Res. 2020. PMID: 31796519 Clinical Trial.
A tissue biomarker-based model that identifies patients with a high risk of distant metastasis and differential survival by length of androgen deprivation therapy in RTOG protocol 92-02.
Pollack A, Dignam JJ, Diaz DA, Wu Q, Stoyanova R, Bae K, Dicker AP, Sandler H, Hanks GE, Feng FY. Pollack A, et al. Among authors: wu q. Clin Cancer Res. 2014 Dec 15;20(24):6379-88. doi: 10.1158/1078-0432.CCR-14-0075. Epub 2014 Oct 7. Clin Cancer Res. 2014. PMID: 25294917 Free PMC article.
High End-of-Life Health Care Utilization in a Contemporary Cohort of Head and Neck Cancer Patients Treated with Immune Checkpoint Inhibitors.
Chalker C, Santana-Davila R, Voutsinas JM, Wu QV, Hwang V, Baik CS, Lee S, Barber B, Futran ND, Houlton JJ, Laramore GE, Liao JJ, Parvathaneni U, Martins RG, Eaton KD, Rodriguez CP. Chalker C, et al. J Palliat Med. 2022 Apr;25(4):614-619. doi: 10.1089/jpm.2021.0323. Epub 2021 Nov 30. J Palliat Med. 2022. PMID: 34847733
Development of a prognostic signature for overall survival using peripheral blood biomarkers in head and neck squamous cell carcinoma treated with immune checkpoint inhibitors.
Pan C, Ng K, Voutsinas J, Barber B, Rizvi ZH, Marchiano E, Ferrandino RM, Futran N, Laramore GE, Liao JJ, Parvathaneni U, Panjwani N, Martins RG, Rodriguez CP, Wu QV. Pan C, et al. BMC Cancer. 2024 Nov 15;24(1):1406. doi: 10.1186/s12885-024-13051-6. BMC Cancer. 2024. PMID: 39543541 Free PMC article.
Prospective Study of Serial 18F-FDG PET and 18F-Fluoride PET to Predict Time to Skeletal-Related Events, Time to Progression, and Survival in Patients with Bone-Dominant Metastatic Breast Cancer.
Peterson LM, O'Sullivan J, Wu QV, Novakova-Jiresova A, Jenkins I, Lee JH, Shields A, Montgomery S, Linden HM, Gralow J, Gadi VK, Muzi M, Kinahan P, Mankoff D, Specht JM. Peterson LM, et al. J Nucl Med. 2018 Dec;59(12):1823-1830. doi: 10.2967/jnumed.118.211102. Epub 2018 May 10. J Nucl Med. 2018. PMID: 29748233 Free PMC article.
Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patients.
Chalker C, Voutsinas JM, Wu QV, Santana-Davila R, Hwang V, Baik CS, Lee S, Barber B, Futran ND, Houlton JJ, Laramore GE, Liao JJ, Parvathaneni U, Martins RG, Eaton KD, Rodriguez CP. Chalker C, et al. Cancer Med. 2022 Nov;11(22):4104-4111. doi: 10.1002/cam4.4722. Epub 2022 Mar 29. Cancer Med. 2022. PMID: 35349227 Free PMC article.
Neutrophil to lymphocyte ratio and peripheral blood biomarkers correlate with survival outcomes but not response among head and neck and salivary cancer treated with pembrolizumab and vorinostat.
Pan C, Wu QV, Voutsinas J, Houlton JJ, Barber B, Futran N, Laramore GE, Liao JJ, Parvathaneni U, Martins RG, Fromm JR, Rodriguez CP. Pan C, et al. Head Neck. 2023 Feb;45(2):391-397. doi: 10.1002/hed.27252. Epub 2022 Nov 22. Head Neck. 2023. PMID: 36412064 Free PMC article. Clinical Trial.
25,122 results
You have reached the last available page of results. Please see the User Guide for more information.